论文部分内容阅读
为了了解增殖细胞核抗原（ＰＣＮＡ）与前列腺癌的病理分级、临床分期及预后的关系，我们采用免疫组织化学Ｓ－Ｐ法对４３例前列腺癌组织中ＰＣＮＡ进行检测，并与临床随访结果进行对比。结果显示：前列腺癌ＰＣＮＡ表达与分级、分期及预后均相关（Ｐ＜０．０５），ＰＣＮＡ高表达组（３．４级）术后生存率明显低于低表达组（１、２级）。结果表明：ＰＣＮＡ是判断细胞增殖程度的重要指标，对肿瘤演变、术后随访及治疗有一定的指导意义，对估计前列腺癌的恶性程度及推测预后亦具有重要参考价值。
In order to understand the relationship between PCNA and pathological grade, clinical stage and prognosis of prostate cancer, we used immunohistochemical S-P method to detect PCNA in 43 cases of prostate cancer and compared with clinical follow-up results. The results showed that the expression of PCNA in prostate cancer was correlated with the grade, stage and prognosis (P <0.05). The postoperative survival rate of PCNA high expression group (3.4 grade) was significantly lower than that of the low expression group (grade 1,2). The results showed that: PCNA is an important index to judge the degree of cell proliferation, which has some guiding significance for tumor evolution, postoperative follow-up and treatment. It also has important reference value for estimating the malignancy and prognosis of prostate cancer.